The year 2025 saw meaningful progress in autologous cellular therapy for melanoma and other solid tumors, building on regulatory advances in 2024. Clinical and translational developments described in the review emphasize durable clinical benefit for some platforms, emergence of engineered and programmable cellular constructs, and advancing evidence for personalized neoantigen strategies. The field is shifting toward therapies that improve durability while addressing logistical and toxicity limitations of earlier approaches.
Lifileucel, the first Food and Drug Administration–approved tumor-infiltrating lymphocyte (TIL) therapy for advanced melanoma, demonstrated durable efficacy in a 5-year analysis of the C-144-01 trial. In this heavily pretreated population, the study reported an objective response rate (ORR) of 31.4%, with prolonged responses observed over the follow-up period. These long-term data support lifileucel's clinical activity in a population with limited therapeutic options.
Real-world data further corroborated lifileucel's effectiveness. The review notes that observational experience showed higher ORR in some real-world cohorts, which the authors attribute to factors such as earlier lines of therapy and differences in patient selection compared with the pivotal trial population. These findings suggest that lifileucel can be effective outside of the strictly defined clinical-trial setting, though outcomes may vary based on treatment timing and patient characteristics.
Targeting preferentially expressed antigen in melanoma (PRAME) via T-cell receptor (TCR) T-cell therapy emerged as a promising strategy. The PRAME-targeted product anzu-cel (IMA203) produced encouraging activity in a phase 1 study, with an ORR of approximately 50% in checkpoint inhibitor–refractory melanoma. Responses were described as durable and toxicity was manageable in the early-phase data, supporting PRAME as a high-value antigenic target across multiple tumor types.
Next-generation engineered TIL approaches aim to address limitations of traditional TIL therapy, particularly the need for high-dose interleukin-2 (IL-2) support. OBX-115 is an IL-2–independent TIL platform that expresses membrane-bound IL-15 under regulation by acetazolamide. Initial phase 1 data for OBX-115 showed early clinical activity with an ORR of 67% in the initial cohort reported in the review. The article also highlights broader strategies such as CRISPR-mediated gene editing and checkpoint disruption to produce programmable, self-sustaining cellular products that may reduce systemic cytokine requirements and improve persistence.
Personalized neoantigen approaches advanced in 2025 with early clinical validation across adoptive T-cell platforms and mRNA vaccines. These strategies demonstrated evidence of immune activation and, in melanoma, improved recurrence-free survival in early studies. The review frames neoantigen-directed therapies as an evolving personalized modality that can complement engineered cell therapies by focusing immune responses on patient-specific tumor antigens.
Afamitresgene autoleucel (afami-cel), a TCR-T therapy directed against MAGE-A4, showed durable efficacy in synovial sarcoma and expanding activity across other solid tumors. The review presents afami-cel as establishing proof of concept for TCR-T approaches in solid tumors, demonstrating that antigen-directed TCR therapies can deliver meaningful clinical responses beyond melanoma.
Collectively, these developments position autologous cellular therapy as an evolving standard of care in melanoma and a promising therapeutic modality across multiple solid tumors. Key themes for ongoing work include improving accessibility and manufacturing scalability, overcoming mechanisms of resistance, optimizing combinations with other systemic therapies, and advancing programmable engineering to enhance persistence and safety. The review underscores that while several products have shown durable activity, continued clinical evaluation and real-world implementation studies will be essential to define optimal sequencing, patient selection, and long-term outcomes.